The advisors of the US Centers for Disease Control and Prevention (CDC) recommended on Tuesday the use of Novavax COVID-19 vaccine for people aged above 18 years old.
The US government secured more than three million doses of the vaccine as the FDA is about to release the first package of the doses, and they will be distributed in the upcoming days.
Last month, a panel of independent vaccine experts recommend that the Food and Drug Administration (FDA) authorize the Novavax vaccine for giving second booster shots to the US residents.
The recommendation of the experts came a few days after the release of a report about the risk of heart inflammation risk.
Novavax is a protein-based vaccine that uses traditional technology against flu viruses, therefore, many experts are interested in installing another traditional-technology based vaccine, especially after the latest restrictions imposed on Johnson & Johnson COVID-19 vaccine.
Director of the Mayo Clinic’s Vaccine Research Group and a paid consultant to Novavax Gregory Poland said: “It’s important to have choices in vaccine platforms in a pandemic that is constantly evolving.”
On his side, the FDA’s director of the Center for Biologics Evaluation and Research Peter Marks explained: “Having a protein-based alternative may be more comfortable for some in terms of their acceptance of vaccine.”
Last year, Novavax Inc, and Serum Institute of India applied to the World Health Organization (WHO) for having the emergency use approval for their COVID-19 vaccine, Novavax.
Follow the latest news on Google News
